CN103728402A - 检测化合物中溶剂残留量的gc方法 - Google Patents
检测化合物中溶剂残留量的gc方法 Download PDFInfo
- Publication number
- CN103728402A CN103728402A CN201210390647.0A CN201210390647A CN103728402A CN 103728402 A CN103728402 A CN 103728402A CN 201210390647 A CN201210390647 A CN 201210390647A CN 103728402 A CN103728402 A CN 103728402A
- Authority
- CN
- China
- Prior art keywords
- solution
- temperature
- solvent
- acetic acid
- chromatographic column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002904 solvent Substances 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000004817 gas chromatography Methods 0.000 title description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 212
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 70
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 69
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 68
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000012159 carrier gas Substances 0.000 claims abstract description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000007789 gas Substances 0.000 claims abstract description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 23
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 17
- 238000000926 separation method Methods 0.000 claims abstract description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 229910052786 argon Inorganic materials 0.000 claims abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 126
- 239000000243 solution Substances 0.000 claims description 120
- 238000012360 testing method Methods 0.000 claims description 70
- 239000013558 reference substance Substances 0.000 claims description 31
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims description 28
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 28
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 25
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 25
- 238000011067 equilibration Methods 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- 238000010792 warming Methods 0.000 claims description 20
- 238000005070 sampling Methods 0.000 claims description 16
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 14
- -1 carbostyril compound Chemical class 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 9
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 7
- 239000001307 helium Substances 0.000 claims description 5
- 229910052734 helium Inorganic materials 0.000 claims description 5
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 5
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002549 enoxacin Drugs 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001699 ofloxacin Drugs 0.000 claims description 4
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 4
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 3
- FZLRVVLMSXBKDS-UHFFFAOYSA-N COCCN1C=C(C(=O)C=2C1=CC1=C(C=2)OCO1)C(=O)O Chemical compound COCCN1C=C(C(=O)C=2C1=CC1=C(C=2)OCO1)C(=O)O FZLRVVLMSXBKDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 229960003923 gatifloxacin Drugs 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 3
- 229960003702 moxifloxacin Drugs 0.000 claims description 3
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001180 norfloxacin Drugs 0.000 claims description 3
- 229960004236 pefloxacin Drugs 0.000 claims description 3
- 229960001732 pipemidic acid Drugs 0.000 claims description 3
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003965 capillary gas chromatography Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 28
- 238000001514 detection method Methods 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 150000007660 quinolones Chemical class 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000010812 external standard method Methods 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 229960004444 piromidic acid Drugs 0.000 description 3
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- ABQYZRZVRIPTPI-UHFFFAOYSA-N miloxacin Chemical compound C1=C2N(OC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 ABQYZRZVRIPTPI-UHFFFAOYSA-N 0.000 description 1
- 229950007835 miloxacin Drugs 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
平衡时间(min) | 30 | 45 | 60 |
峰面积 | 102.019 | 102.778 | 99.093 |
样品 | 1 | 2 | 3 | 4 | 5 | 6 | RSD% |
峰面积 | 39.679 | 40.389 | 39.008 | 39.656 | 38.116 | 38.122 | 2.34 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210390647.0A CN103728402B (zh) | 2012-10-15 | 2012-10-15 | 检测化合物中溶剂残留量的gc方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210390647.0A CN103728402B (zh) | 2012-10-15 | 2012-10-15 | 检测化合物中溶剂残留量的gc方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103728402A true CN103728402A (zh) | 2014-04-16 |
CN103728402B CN103728402B (zh) | 2017-05-24 |
Family
ID=50452566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210390647.0A Expired - Fee Related CN103728402B (zh) | 2012-10-15 | 2012-10-15 | 检测化合物中溶剂残留量的gc方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103728402B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198596A (zh) * | 2014-05-21 | 2014-12-10 | 江苏德峰药业有限公司 | 一种丙基硫氧嘧啶钠盐溶剂残留的检测方法 |
CN104297365A (zh) * | 2014-09-17 | 2015-01-21 | 成都克莱蒙医药科技有限公司 | 盐酸莫西沙星中残留溶剂醋酸的测定方法 |
CN104502491A (zh) * | 2015-01-20 | 2015-04-08 | 陕西汉江药业集团股份有限公司 | 一种顶空进样测定原料药奥芬达唑溶剂残留的方法 |
CN104597151A (zh) * | 2014-12-25 | 2015-05-06 | 上海景峰制药有限公司 | 一种蛋黄卵磷脂溶剂残留检测方法 |
CN104820041A (zh) * | 2015-05-14 | 2015-08-05 | 中唯炼焦技术国家工程研究中心有限责任公司 | 一种分析芴类衍生物中多种残留有机溶剂的方法 |
CN105181842A (zh) * | 2015-09-09 | 2015-12-23 | 上海信谊百路达药业有限公司 | 一种银杏内酯b残留溶剂的检测方法 |
CN105424859A (zh) * | 2015-12-14 | 2016-03-23 | 山东凯盛新材料有限公司 | 尾气回收二氧化硫中杂质的检测方法 |
CN106153749A (zh) * | 2015-04-07 | 2016-11-23 | 江苏宝众宝达药业有限公司 | 检验氯苯达诺盐酸盐原料药中残留溶剂的方法 |
CN106596821A (zh) * | 2016-12-12 | 2017-04-26 | 中国测试技术研究院 | 一种农药制剂中有机溶剂的快速测定方法 |
CN107271586A (zh) * | 2017-06-26 | 2017-10-20 | 江苏悦兴医药技术有限公司 | 一种利伐沙班中间体中残留溶剂残留量的分析方法 |
CN108828124A (zh) * | 2018-06-27 | 2018-11-16 | 湖北省宏源药业科技股份有限公司 | 甲硝唑中残留甲酸甲酯和甲醇限度检查方法 |
CN109507336A (zh) * | 2018-12-29 | 2019-03-22 | 湖北博凯医药科技有限公司 | 一种检测丙谷二肽中有机溶剂残留的方法 |
CN109541112A (zh) * | 2019-01-16 | 2019-03-29 | 苏州众合生物医药科技有限公司 | 一种检测重组人源抗TNF-α项目清洁验证样品中乙醇残留的方法 |
CN111175413A (zh) * | 2020-03-18 | 2020-05-19 | 山东滨州智源生物科技有限公司 | 一种磺丁基倍他环糊精钠原料或其制剂中4-氯丁醇醋酸酯含量的检测方法 |
CN111751459A (zh) * | 2020-05-27 | 2020-10-09 | 济川药业集团有限公司 | 一种同时检测西他沙星中多种残留溶剂的方法 |
CN112034069A (zh) * | 2020-09-09 | 2020-12-04 | 安徽丰原药业股份有限公司 | 一种检测乳酸钠溶液中甲醇残留的方法 |
CN112461971A (zh) * | 2020-11-20 | 2021-03-09 | 常州寅盛药业有限公司 | 一种福比他韦及其检定方法 |
CN114441677A (zh) * | 2022-01-25 | 2022-05-06 | 上海方予健康医药科技有限公司 | 一种同时检测三苯乙酸维兰特罗多种基因杂质的方法 |
CN114740113A (zh) * | 2022-04-12 | 2022-07-12 | 四川汇宇制药股份有限公司 | 聚丙烯酸中残留溶剂和/或有关物质的分离检测方法 |
CN114740103A (zh) * | 2022-03-16 | 2022-07-12 | 天津键凯科技有限公司 | 一种聚多卡醇低聚物分布检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0933507A (ja) * | 1995-07-17 | 1997-02-07 | Hitachi Cable Ltd | エナメル線の残留有機溶剤測定方法 |
JP2002168844A (ja) * | 2000-11-30 | 2002-06-14 | Hitachi Chemical Dupont Microsystems Ltd | ポリイミド前駆体樹脂膜の残存溶媒量測定方法及びこの方法によるベーク条件出し方法 |
CN101285813A (zh) * | 2008-04-28 | 2008-10-15 | 长春迈灵生物工程有限公司 | 一种牛磺罗定的质量检测方法 |
CN102109499A (zh) * | 2009-12-23 | 2011-06-29 | 上海新先锋药业有限公司 | 用气相色谱同时检测药物中丙酮和乙酸乙酯残留的方法 |
-
2012
- 2012-10-15 CN CN201210390647.0A patent/CN103728402B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0933507A (ja) * | 1995-07-17 | 1997-02-07 | Hitachi Cable Ltd | エナメル線の残留有機溶剤測定方法 |
JP2002168844A (ja) * | 2000-11-30 | 2002-06-14 | Hitachi Chemical Dupont Microsystems Ltd | ポリイミド前駆体樹脂膜の残存溶媒量測定方法及びこの方法によるベーク条件出し方法 |
CN101285813A (zh) * | 2008-04-28 | 2008-10-15 | 长春迈灵生物工程有限公司 | 一种牛磺罗定的质量检测方法 |
CN102109499A (zh) * | 2009-12-23 | 2011-06-29 | 上海新先锋药业有限公司 | 用气相色谱同时检测药物中丙酮和乙酸乙酯残留的方法 |
Non-Patent Citations (4)
Title |
---|
杨先启 等: "顶空气相色谱法测定盐酸吉西他滨中的残留溶剂", 《中国药师》 * |
毛威: "顶空气相色谱法测定盐酸安非他酮中的有机溶剂残留", 《药物分析杂志》 * |
王岩: "毛细管气相色谱法测定萘哌地尔中的残留溶剂", 《药物分析杂志》 * |
邬方宁: "毛细管法测定莫西沙星中的有机溶剂残留量", 《药物评价研究》 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198596A (zh) * | 2014-05-21 | 2014-12-10 | 江苏德峰药业有限公司 | 一种丙基硫氧嘧啶钠盐溶剂残留的检测方法 |
CN104297365A (zh) * | 2014-09-17 | 2015-01-21 | 成都克莱蒙医药科技有限公司 | 盐酸莫西沙星中残留溶剂醋酸的测定方法 |
CN104297365B (zh) * | 2014-09-17 | 2015-12-02 | 成都克莱蒙医药科技有限公司 | 盐酸莫西沙星中残留溶剂醋酸的测定方法 |
CN104597151A (zh) * | 2014-12-25 | 2015-05-06 | 上海景峰制药有限公司 | 一种蛋黄卵磷脂溶剂残留检测方法 |
CN104502491A (zh) * | 2015-01-20 | 2015-04-08 | 陕西汉江药业集团股份有限公司 | 一种顶空进样测定原料药奥芬达唑溶剂残留的方法 |
CN106153749A (zh) * | 2015-04-07 | 2016-11-23 | 江苏宝众宝达药业有限公司 | 检验氯苯达诺盐酸盐原料药中残留溶剂的方法 |
CN104820041A (zh) * | 2015-05-14 | 2015-08-05 | 中唯炼焦技术国家工程研究中心有限责任公司 | 一种分析芴类衍生物中多种残留有机溶剂的方法 |
CN105181842A (zh) * | 2015-09-09 | 2015-12-23 | 上海信谊百路达药业有限公司 | 一种银杏内酯b残留溶剂的检测方法 |
CN105424859A (zh) * | 2015-12-14 | 2016-03-23 | 山东凯盛新材料有限公司 | 尾气回收二氧化硫中杂质的检测方法 |
CN106596821A (zh) * | 2016-12-12 | 2017-04-26 | 中国测试技术研究院 | 一种农药制剂中有机溶剂的快速测定方法 |
CN106596821B (zh) * | 2016-12-12 | 2018-07-20 | 中国测试技术研究院 | 一种农药制剂中有机溶剂的快速测定方法 |
CN107271586A (zh) * | 2017-06-26 | 2017-10-20 | 江苏悦兴医药技术有限公司 | 一种利伐沙班中间体中残留溶剂残留量的分析方法 |
CN108828124A (zh) * | 2018-06-27 | 2018-11-16 | 湖北省宏源药业科技股份有限公司 | 甲硝唑中残留甲酸甲酯和甲醇限度检查方法 |
CN109507336A (zh) * | 2018-12-29 | 2019-03-22 | 湖北博凯医药科技有限公司 | 一种检测丙谷二肽中有机溶剂残留的方法 |
CN109507336B (zh) * | 2018-12-29 | 2021-10-01 | 湖北博凯医药科技有限公司 | 一种检测丙谷二肽中有机溶剂残留的方法 |
CN109541112A (zh) * | 2019-01-16 | 2019-03-29 | 苏州众合生物医药科技有限公司 | 一种检测重组人源抗TNF-α项目清洁验证样品中乙醇残留的方法 |
CN111175413B (zh) * | 2020-03-18 | 2022-08-02 | 山东滨州智源生物科技有限公司 | 一种磺丁基倍他环糊精钠原料或其制剂中4-氯丁醇醋酸酯含量的检测方法 |
CN111175413A (zh) * | 2020-03-18 | 2020-05-19 | 山东滨州智源生物科技有限公司 | 一种磺丁基倍他环糊精钠原料或其制剂中4-氯丁醇醋酸酯含量的检测方法 |
CN111751459A (zh) * | 2020-05-27 | 2020-10-09 | 济川药业集团有限公司 | 一种同时检测西他沙星中多种残留溶剂的方法 |
CN112034069A (zh) * | 2020-09-09 | 2020-12-04 | 安徽丰原药业股份有限公司 | 一种检测乳酸钠溶液中甲醇残留的方法 |
CN115286639A (zh) * | 2020-11-20 | 2022-11-04 | 常州寅盛药业有限公司 | 一种福比他韦及其检定方法 |
CN112461971B (zh) * | 2020-11-20 | 2022-10-04 | 常州寅盛药业有限公司 | 一种福比他韦及其检定方法 |
CN112461971A (zh) * | 2020-11-20 | 2021-03-09 | 常州寅盛药业有限公司 | 一种福比他韦及其检定方法 |
CN115286639B (zh) * | 2020-11-20 | 2023-09-22 | 常州寅盛药业有限公司 | 一种福比他韦及其检定方法 |
CN114441677A (zh) * | 2022-01-25 | 2022-05-06 | 上海方予健康医药科技有限公司 | 一种同时检测三苯乙酸维兰特罗多种基因杂质的方法 |
CN114441677B (zh) * | 2022-01-25 | 2024-06-11 | 上海方予健康医药科技有限公司 | 一种同时检测三苯乙酸维兰特罗多种基因杂质的方法 |
CN114740103A (zh) * | 2022-03-16 | 2022-07-12 | 天津键凯科技有限公司 | 一种聚多卡醇低聚物分布检测方法 |
CN114740113A (zh) * | 2022-04-12 | 2022-07-12 | 四川汇宇制药股份有限公司 | 聚丙烯酸中残留溶剂和/或有关物质的分离检测方法 |
CN114740113B (zh) * | 2022-04-12 | 2023-10-20 | 四川汇宇制药股份有限公司 | 聚丙烯酸中残留溶剂和/或有关物质的分离检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103728402B (zh) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103728402A (zh) | 检测化合物中溶剂残留量的gc方法 | |
Cheng et al. | A generic static headspace gas chromatography method for determination of residual solvents in drug substance | |
Krishnan et al. | CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility | |
CN110320293B (zh) | 一种测定苯酞类化合物中残留溶剂的方法 | |
CN103822992B (zh) | 一种电子烟烟液中烟碱、麦斯明、新烟碱、假木贼碱和可替宁含量的气相色谱测定方法 | |
Klick et al. | Validation of a generic analytical procedure for determination of residual solvents in drug substances | |
Melo et al. | Automated determination of rifampicin in plasma samples by in-tube solid-phase microextraction coupled with liquid chromatography | |
CN103487541A (zh) | 一种同时检测头孢曲松钠中多种残留溶剂的方法 | |
CN103822997A (zh) | 一种利伐沙班中间体的分析检测方法 | |
CN103185759A (zh) | 奥氮平中溶剂残留的检测方法及其应用 | |
CN103592379B (zh) | 一种奥美拉唑有关物质的分析方法 | |
Caris et al. | Automated analysis of lidocaine and its metabolite in plasma by in‐tube solid‐phase microextraction coupled with LC‐UV for pharmacokinetic study | |
CN103487518B (zh) | 注射用盐酸克林霉素杂质的检测方法及含量测定方法 | |
Kadi et al. | High throughput quantitative bioanalytical LC/MS/MS determination of gemifloxacin in human urine | |
Momin et al. | Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation | |
ALOthman et al. | Enantiomeric resolution of quinolones on crown ether CSP: Thermodynamics, chiral discrimination mechanism and application in biological samples | |
Ganesh et al. | Retention behaviour of analytes in reversed‐phase high‐performance liquid chromatography—A review | |
CN104297365B (zh) | 盐酸莫西沙星中残留溶剂醋酸的测定方法 | |
CN106198819B (zh) | 顶空气相色谱法测定西格列汀原料药中残留溶剂的方法 | |
Raghuram et al. | GC quantification of cyclopropylamine, diethylamine and triethylamine in active pharmaceutical ingredients | |
CN103543231B (zh) | 一种盐酸美克洛嗪中氯仿残留量的分离分析方法 | |
CN106501386A (zh) | 一种用气相色谱法分离测定阿立哌唑中二乙醇胺含量的方法 | |
CN104535693A (zh) | 一种加米霉素含量检测方法 | |
Klok et al. | Residual solvent analysis by gas chromatography in radiopharmaceutical formulations containing up to 12% ethanol | |
CN104849388A (zh) | 测定盐酸阿比多尔原料药中有机溶剂残留含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221013 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170524 |
|
CF01 | Termination of patent right due to non-payment of annual fee |